Better Coronavirus Stock: Pfizer or GlaxoSmithKline?

As of May 27, COVID-19 has killed more than 100,000 Americans. Meanwhile, there are now over 100 experimental vaccines being investigated worldwide targeting the SARS-CoV-2 coronavirus, which causes COVID-19. Out of this candidate pool, only 10 vaccines have made it to the clinical or preclinical stages. 

Today, let us look at two companies investigating SARS-CoV-2 vaccines in current or upcoming clinical trials, and determine which one is a better buy.

Image source: Getty Images.

Continue reading

Source Fool.com